Awamedica

What Awamedica does

Awamedica is a Class A pharmaceutical manufacturing company headquartered in Erbil, Iraq, founded in October 2009. It develops, produces, and markets a portfolio of over 180 medicines spanning 11 therapeutic areas (cardiovascular, diabetes, central nervous system, alimentary tract, respiratory, musculo-skeletal, dermatologicals, blood, anti-infectives, systemic hormonal preparations, genito-urinary, and vitamins and minerals) across seven dosage forms (61 tablet, 7 capsule, 11 syrup, 6 suspension, 4 cream, 3 ointment, and 2 gel formulations). Manufacturing is conducted at a single Erbil facility operating under cGMP with ISO 9001, ISO 14001, and ISO 45001 certifications, and includes an in-house Formulation & Development function, a pharmacovigilance system aligned with FDA/EMA/WHO standards, and completed bioequivalence studies for three products.

The company generates revenue primarily through proprietary pharmaceutical product sales distributed across Iraq and the wider MENA region, supplemented by B2B contract manufacturing, secondary packaging, formulation and development services, and licensing and technology transfer arrangements. Named commercial partners include Ajanta Pharma (India) for 18 contract-manufactured products, AL-Razi (Syria) for 4 products, and Pharmacare premium (Malta) for 5 oncology products. Go-to-market relies on direct regional distribution supplemented by event-driven engagement with healthcare professionals through conference sponsorships (Medical Kurdistan, the AWABETIC Endocrine-Cardiorenal Forum series in collaboration with the Kurdistan Doctors Association, and the 1st Endocrinology Iraqi–Kurdistan Summit) and content marketing via blog and social channels.

Production capacity stands at 2 billion tablets and capsules, 18 million liquid bottles, 11 million semisolid tubes, and 8 million suspension and sachet units annually. The company is privately held with 215+ employees (79% local, 21% international), is not publicly listed, and does not disclose revenue. Ownership structure, investors, and financial details constitute data gaps in the available material.

Name

Awamedica

Legal name

Awamedica Co.

Website

https://awamedica.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

101–250 employees

Short description

Awamedica is a privately held Class A pharmaceutical manufacturer headquartered in Erbil, Iraq, producing 180+ generic medicines across 11 therapeutic areas for the Iraqi and MENA markets, and offering GMP-certified contract manufacturing and packaging services to international pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Full-Line Pharmaceutical Wholesalers (HLAIAJAA)

akta.pro secondary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Contract manufacturing
• Formulation development
• Dosage form production

Headquarters

HQ city

Erbil

HQ country

Iraq

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Awamedica develops, manufactures, and markets a portfolio of over 180 high-quality pharmaceutical products across diverse therapeutic areas including cardiovascular, diabetes, central nervous system, alimentary track, respiratory, musculo-skeletal, dermatologicals, blood, anti-infectives, systemic hormonal preparations, genito-urinary, and vitamins & minerals. Products are sold in various dosage forms including tablets (61), capsules (7), syrup (11), suspension (6), cream (4), ointment (3), and gel (2).

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Awamedica is a Class A pharmaceutical manufacturing company that develops, produces, and markets a portfolio of over 180 high-quality medicines in tablets, capsules, syrups, suspensions, creams, ointments, gels, and dry powder sachets across 11 therapeutic areas including cardiovascular, diabetes, CNS, respiratory, and anti-infectives. The company also provides GMP-certified contract manufacturing, secondary packaging, formulation & development, and licensing/technology transfer services to pharmaceutical partners in the MENA region.

Product overview

Awamedica is a Class A pharmaceutical company offering a portfolio of over 180 high-quality medicines across 11 therapeutic areas (cardiovascular, diabetes, CNS, alimentary tract, respiratory, musculo-skeletal, dermatologicals, blood, anti-infectives, systemic hormonal preparations, genito-urinary, and vitamins & minerals). The company manufactures 7 dosage forms: 61 tablet formulations, 7 capsule formulations, 11 syrup formulations, 6 suspension formulations, 4 cream formulations, 3 ointment formulations, and 2 gel formulations. Production capacity includes 2 billion tablets & capsules, 18 million bottles of liquids, 11 million tubes of semisolids, and 8 million units of suspension & sachet per year. Beyond its product portfolio, Awamedica provides contract manufacturing services, secondary packaging services, formulation & development services, and licensing/technology transfer partnerships. Named products include AwaSalazin-SR 500, Parazar Kid Syrup, AwaLibrin, Lomodin Awa, and Omeprazole Awa 20. The company maintains cGMP compliance and ISO certifications across quality, environmental, and occupational health management systems.

Differentiator

Problem solved

Functional benefit

Products and services

• AwaSalazin-SR 500 Mesalazine 500 mg Slow Release Tablet for the treatment of inflammatory bowel disease; packaged as 1x500 bottle.
• Parazar Kid Syrup Paracetamol 125 mg/5 ml syrup formulation for pediatric use; packaged as 1x100 ml bottle.
• AwaLibrin Chlordiazepoxide 5 mg and Clidinium Bromide 2.5 mg combination tablet for gastrointestinal disorders; packaged as 3x10's.
• Lomodin Awa Diphenoxylate 2.5 mg and Atropine sulfate 0.25 mg combination tablet for diarrheal conditions; packaged as 3x10's.
• Omeprazole Awa 20 Omeprazole 20 mg capsule for acid-related disorders; available in 1x14 Bottle or 2x7's Pack formats.
• Contract Manufacturing Services GMP-certified contract manufacturing from raw material sourcing to secondary packaging, managed with precision to the highest global standards; for pharmaceutical companies seeking manufacturing partners.
• Secondary Packaging Services Efficient and compliant secondary packaging of pharmaceutical products meeting specific market requirements and standards.
• Licensing & Technology Transfer Licensing agreements and technology transfer opportunities aligned with portfolio strategy and regional needs.
• Formulation & Development (F&D) Comprehensive formulation services including formulation development, stability testing, process optimization, and regulatory support to accelerate product commercialization.
• Pharmacovigilance Services Continuous monitoring of medicine safety through data collection, risk management, regulatory compliance with FDA/EMA/WHO standards, and ongoing safety reviews.

Quantifiable outcome

• Over 180 high-quality medicines developed and marketed across diverse therapeutic areas
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered minor and core.

• University of Kurdistan HewlêrminorStrategic or Co-development Partner · 11 February 2026Medical Kurdistan 2026 (4th edition) was organized in collaboration with the University of Kurdistan Hewlêr. Awamedica served as Diamond Sponsor for the fourth consecutive year at the conference held 11-13 February 2026 at Rotana Hotel, Erbil, under the theme 'Quality Medical Education at the Service of the Local Population'.
• Ajanta PharmacoreChannel Partner/ Reseller/ DistributorCollaboration with Ajanta Pharma (India) spanning 18 products under contract manufacturing. Awamedica leverages its GMP-certified facility to manufacture pharmaceutical products for Ajanta Pharma, providing reliable, efficient, and high-quality contract manufacturing from raw material sourcing to finished product.
• AL-RazicoreChannel Partner/ Reseller/ DistributorPartnership with AL-Razi (Syria) for 4 products through contract manufacturing, leveraging Awamedica's manufacturing excellence and quality assurance capabilities.
• Pharmacare premiumcoreChannel Partner/ Reseller/ DistributorAlliance with Pharmacare premium (Malta) focused on secondary packaging for 5 oncology products, leveraging Awamedica's secondary packaging services capabilities.
• Kurdistan Doctors Association (KDA)coreStrategic or Co-development PartnerAwamedica organized the AWABETIC Endocrine-Cardiorenal Forum series in collaboration with the Kurdistan Doctors Association (KDA). Scientific meetings were held on 7 May 2026 at Crixus Sarsing Hotel, Duhok, and 11 June 2026 at Ashur Resort, Dukan Lake, Sulaymaniyah. Bioequivalence study findings for three products were presented during dedicated scientific sessions.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Pharco Pharmaceuticals: Egypt-headquartered pharmaceutical manufacturer with one of the largest MENA generics portfolios, including branded generics across multiple therapeutic categories. Closely comparable in regional generics manufacturing, dosage-form breadth, and B2B partnership models.
• Tabuk Pharmaceuticals: Saudi Arabia-headquartered generic pharma manufacturer producing a broad portfolio of branded generics across multiple therapeutic areas for MENA markets. Highly comparable in business model (branded generics, regional distribution) and product breadth.
• SPIMACO Addwaeih: Saudi Arabian pharmaceutical manufacturer with a portfolio spanning multiple therapeutic categories and GMP-certified plants serving Saudi Arabia and export markets. Comparable branded-generics manufacturer with regional distribution focus.
• Eva Pharma: Egypt-based pharmaceutical manufacturer with a wide generics portfolio and growing MENA export footprint. Comparable as a regionally focused generics manufacturer with similar product breadth and dosage-form capabilities.
• Julphar (Gulf Pharmaceutical Industries): UAE-based manufacturer of generics and specialty pharmaceuticals sold across MENA, with comparable GMP-certified plants producing tablets, capsules, syrups, and injectables. Closest regional analog in scale, product mix, and distribution model.
• EIPICO (Egyptian International Pharmaceutical Industries Company): Egypt-based generics manufacturer producing a broad portfolio of finished dosage forms for domestic and regional markets. Comparable in scale, dosage-form breadth (tablets, capsules, liquids, semisolids), and regional generic-pharma positioning.

Others

• AL-Razi Pharmaceutical Industries: Syria-based pharmaceutical manufacturer and existing CMO customer of Awamedica (4 products). Comparable regional generics manufacturer and direct counterparty whose volumes contribute to Awamedica's contract manufacturing utilization.
• Ajanta Pharma: India-headquartered generic pharmaceutical company and existing CMO customer of Awamedica (18 products). Comparable in finished-dosage-form generics manufacturing and a key counterpart whose strategic priorities directly affect Awamedica's CMO utilization.

Broad incumbents

• Cipla: India-based global generic and specialty pharma manufacturer with extensive MENA presence across respiratory, cardiovascular, and other therapeutic areas. Represents both a competitive threat in regional tenders and a potential future CMO partner for Awamedica's surplus capacity.
• Hikma Pharmaceuticals: Jordan-headquartered multinational specialty and generic pharmaceutical manufacturer with a leading MENA presence and extensive US/EU operations. Larger and more diversified than Awamedica but serves overlapping therapeutic areas and customer types across the region.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Awamedica
• LinkedInlinkedin.com/company/awamedica

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Awamedica